Search Results

TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018

TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018 (the “Agreement”), to further improve the terms of its OCABSA financing program in the context of the closing of the acquisition by Sangamo Therapeutics, Inc. of a majority stake of TxCell, have now been completed as planned (see TxCell’s press release dated July 23, 2018). The OCABSA financing program is therefore terminated.

Sangamo Therapeutics, Inc. today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.

Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy.

TxCell SA today reports its financial information for the 3rd quarter of 2018.

The Proposed Acquisition Would Combine Sangamo’s Ex Vivo Gene Editing Capabilities and TxCell’s Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development

TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.

TxCell, a developer of cellular immunotherapies based on regulatory T cells for inflammation, autoimmunity and transplantation, today announces its financial calendar for 2018.

Shares of France’s TxCell S.A. have skyrocketed about 150 percent this morning after Sangamo Therapeutics announced it was acquiring a majority stake in the company for €72 million (about $82 million) in a cash deal.

TxCell today reports its fourth quarter 2017 financials and provides an update on its financing.